|Articles|October 13, 2020

J&J Pauses Vaccine Trials Due to Unexplained Illness in Participant

The company made the announcement Monday night.

Johnson & Johnson (J&J) announced Monday night they had paused their COVID-19 clinical trials due to an unexplained illness in a vaccine participant.

“We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the phase 3 ENSEMBLE trial,” the company said in a statement they released last night.

The company did not offer any more information about the illness. “We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”

In late September, J&J moved into a phase 3 trial with its vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S, which is an adenovirus based vaccine.

“Based on these results and following discussions with the U.S. Food and Drug Administration (FDA), ENSEMBLE will enroll up to 60,000 volunteers across three continents and will study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19,” said in a statement at that time.

Earlier that same month, AstraZeneca and the University of Oxford has been put their vaccine trials on hold due to a suspected serious adverse event reaction in a UK-based participant.

The AstraZeneca and the University of Oxford trials in the UK have since resumed but not in the United States.


Related to this article

Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.